Smith & Nephew PLC Sponsored ADR Stock

$30.28

2.54% yesterday

NYSE, Jul 11, 10:10 pm CET

ISIN

US83175M2052

Symbol

SNN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Smith & Nephew PLC Sponsored ADR Stock price

$30.28

-8.40 21.72% 5Y

NYSE, Closing price Fri, Jul 11 2025

-0.79 2.54%

ISIN

US83175M2052

Symbol

SNN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$13.6b

Enterprise Value

$16.3b

Net debt

$2.7b

Cash

$619.0m

Shares outstanding

874.4m

Valuation (TTM | estimate)

P/E

64.4 | 28.6

P/S

2.3 | 2.2

EV/Sales

2.8 | 2.6

EV/FCF

27.0

P/B

2.6

Dividends

DPS

$0.75

Yield 1Y | 5Y

2.5% | 2.3%

Growth 1Y | 5Y

0.0% | 0.6%

Payout 1Y | 3Y

159.6% | 218.5%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$5.8b | $6.2b

EBITDA

$1.0b | $1.6b

EBIT

$841.0m | $1.1b

Net Income

$412.0m | $925.6m

Free Cash Flow

$606.0m

Growth (TTM | estimate)

Revenue

4.7% | 6.9%

EBITDA

24.7% | 45.3%

EBIT

37.9% | 22.3%

Net Income

56.7% | 124.7%

Free Cash Flow

234.8%

Financial Health

Equity Ratio

50.9%

Return on Equity

7.8%

ROCE

9.5%

ROIC

8.4%

Debt/Equity

0.6

EPS

$0.5

FCF per Share

$0.7

Short interest

0.6%

Employees

17k

Rev per Employee

$330.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Smith & Nephew PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

25 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

13x Buy

52%

11x Hold

44%

More details on Analyst Estimates Including Price Targets

25 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

Buy

52%

Hold

44%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Smith & Nephew PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	5,810 5,810	5% 5% 100%
- Direct Costs	1,764 1,764	2% 2% 30%
Gross Profit	4,046 4,046	6% 6% 70%
- Selling and Administrative Expenses	2,738 2,738	3% 3% 47%
- Research and Development Expense	289 289	15% 15% 5%
EBITDA	1,019 1,019	25% 25% 18%
- Depreciation and Amortization	178 178	14% 14% 3%
EBIT (Operating Income) EBIT	841 841	38% 38% 14%
Net Profit	412 412	57% 57% 7%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Smith & Nephew PLC Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

5 days ago

Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle.

Neutral

GlobeNewsWire

●

18 days ago

Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fractures

The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific ...

Neutral

GlobeNewsWire

●

19 days ago

Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.

More Smith & Nephew PLC Sponsored ADR News

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Deepak Nath
Employees	17,349
Founded	1856
Website	www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now